Heparin-induced thrombocytopenia

Abstract

Heparin-induced thrombocytopenia (HIT) is complex clinical-biological syndrome associated with high morbidity and mortality if not recognized in time. HIT occurs after heparin exposure, regardless of the type, dose, and route of administration. The main topics to be discussed in this review are the risk factors, pathophysiology and clinical manifestation. Current guidelines on diagnostic algorithm and promising therapeutic options for fondaparinux and direct oral anticoagulants (DOAC) in HIT are presented.